IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
79 hedge funds and large institutions have $20.5M invested in IGM Biosciences in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 21 increasing their positions, 26 reducing their positions, and 25 closing their positions.
3,100% more call options, than puts
Call options by funds: $32K | Put options by funds: $1K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 85 → 79 (-6)
11.97% less ownership
Funds ownership: 63.74% → 51.77% (-12%)
19% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 26
24% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 25
85% less capital invested
Capital invested by funds: $133M → $20.5M (-$112M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$617K |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$444K |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
+$221K |
| 4 |
Two Sigma Advisers
New York
|
+$168K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$160K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.56M |
| 2 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$870K |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$770K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$617K |
IGMS Hedge Fund Activity: Q1 2025 in Review
79 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q1 2025, worth a combined $20.5M — down 85% from $133M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of IGMS and 19 opened new positions — a net loss of 6 holders — while 26 trimmed existing stakes and 21 added.
The largest buyer was GSA Capital Partners, adding an estimated $617K. The largest seller was T. Rowe Price Associates, cutting an estimated $6.56M.
- 79 institutional investors held IGM Biosciences (IGMS) as of Q1 2025, down from 85 in Q4 2024.
- Funds reported $20.5M of IGM Biosciences stock for Q1 2025, down 85% quarter-over-quarter.
- 19 funds opened new IGM Biosciences positions in Q1 2025 and 25 closed out, a net change of -6 holders.
- The largest IGM Biosciences buyer in Q1 2025 was GSA Capital Partners, an estimated $617K added.
- The largest IGM Biosciences seller in Q1 2025 was T. Rowe Price Associates, an estimated $6.56M sold.
Based on aggregated 13F filings for Q1 2025.